KPV Dosage: What Community Protocols Report
Last updated September 27, 2026 · Reviewed by Grey Peptides Editorial Board · ✓ Primary-sourced
← KPV encyclopedia entry · See also: BPC-157 dosage · Regulatory tracker
KPV is investigational and not FDA approved, with an evidence base that is largely preclinical. There is no label or validated human dose. The figures below reflect community practice, documented for education — not instructions for use.
Educational information, not medical advice. The doses on this page come from approved labels, published studies and, where no study exists, amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
The short version
KPV is a tripeptide — lysine-proline-valine — that corresponds to the C-terminal end of α-melanocyte-stimulating hormone (α-MSH). It carries α-MSH's anti-inflammatory activity without the pigmentation effects of the full hormone, which is why it is studied for inflammatory conditions, especially in the gut (inflammatory bowel disease models). As with most peptides here, the appealing biology lives mostly in animal and cell studies, so any human dose is an extrapolation.
What community protocols report
Community-reported. Amounts users report, recorded for education. Not a recommendation, and not a dose any study has shown to be safe or effective.
| Parameter | Commonly reported |
|---|---|
| Amount | ~200–500 mcg/day |
| Route | Oral (for gut focus) or subcutaneous |
| Pattern | Once daily, time-limited |
The route choice tracks the goal: oral dosing is favored when the target is gut inflammation (delivering the peptide where it is meant to act), while subcutaneous is used for a more systemic intent. Both are community conventions rather than validated regimens.
Where KPV stands legally
KPV was on the FDA 503A Category 2 list and, on April 15, 2026, was among the peptides removed from Category 2 (FDA announced the removals that day, effective within seven days; its Category 2 page reflects them as of April 22, 2026) after nominations were withdrawn — which is not approval. On July 23, 2026 the PCAC voted 8–6, with one abstention, to recommend it for the 503A Bulks List (the vote and FDA's briefing). A recommendation is not a rule: as of September 27, 2026, FDA has not acted on it, and it remains outside the approved-medicine framework; see the Regulatory Status Tracker.
Reconstitution basics
Injectable KPV is supplied as a lyophilized powder requiring reconstitution with bacteriostatic water; oral forms are also sold. For the injectable route, the Reconstitution Calculator converts vial strength and diluent volume into an exact draw — though it cannot verify the contents of an unregulated vial.
Frequently asked questions
Does oral KPV survive digestion?
Part of KPV's interest is evidence in gut models that it can act locally on intestinal inflammation, which is the rationale for oral use in that setting; systemic oral bioavailability is a separate, less-settled question.
Is it related to BPC-157?
They are both discussed for gut and inflammation but are unrelated molecules with different mechanisms. See the BPC-157 dosage page.
Is it approved now that it's off Category 2?
No. Removal from Category 2 is procedural, not approval: on July 23, 2026 the PCAC voted 8–6, with one abstention, to recommend it for the 503A Bulks List, but as of September 27, 2026 FDA has not acted on it, and it is not an approved medicine.
Sources
- Dalmasso G, et al. "PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation." Gastroenterology. 2008;134:166–178.
- U.S. FDA — 503A bulk drug substances list update and Category 2 removals, April 15, 2026; PCAC meeting notice for July 23–24, 2026.
Medical disclaimer: Education only, not medical advice. KPV is investigational and not approved for human use. Dosing figures reflect community reports, not a recommendation. Do not self-administer; consult a licensed clinician.